Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fireside Chat: Monday, March 2, 2026 at 11:10 a.m. Eastern Time in Boston, MA The Citizens Life Sciences Conference Fireside Chat: Wednesday, March 11, 2026 at 1:05 p.m. Eastern Time in Miami Beach, FL Live webcasts will be accessible on the company's website, acadia.com, under the investors section.

Business Wire • Feb 23, 2026

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 18, 2026

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until May 24, 20.

Business Wire • Feb 4, 2026

Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU

ACAD expects a negative CHMP opinion on trofinetide marketing application for Rett syndrome, likely delaying a potential EU approval.

Zacks Investment Research • Feb 3, 2026

5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates

Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.

Zacks Investment Research • Feb 3, 2026

Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards

Class A shares of the Alger Weatherbie Specialized Growth Fund outperformed the Russell 2500 Growth Index during the fourth quarter of 2025. Natera, Inc., ACADIA Pharmaceuticals Inc., and Glaukos Corp were among the top contributors to performance. FirstService Corp, AAR CORP., and Kratos Defense & Security Solutions, Inc. were among the top detractors from performance.

Seeking Alpha • Feb 3, 2026

Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again

Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Feb 2, 2026

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on its Marketing Authorization Application (MAA) for trofinetide for the treatment of Rett syndrome, following its recent CHMP oral explanation. Subject to the outcome of the CHMP vote in February, Acadia intends to request a re-examination of the opinion b.

Business Wire • Feb 2, 2026

FTRE or ACAD: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Jan 28, 2026

ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026